Microbiotica, a clinical-stage biopharma company, has presented new data on MB097 at the AACR IO meeting held in Los Angeles. MB097 is an oral precision microbiome medicine, currently in development as a co-therapy with KEYTRUDA (pembrolizumab) for advanced melanoma patients. Source: Pharmatimes 26/2/25